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A ketogenic diet is an important therapy used in the control of drug-refractory seizures. Many studies have
shown that children and adolescents following ketogenic diets exhibit an over 50% reduction in seizure
frequency, which is considered to be clinically relevant. These benefits are based on a diet containing high fat
(approximately 90% fat) for 24 months. This dietary model was proposed in the 1920s and has produced
variable clinical responses. Previous studies have shown that the mechanisms underlying seizure control involve
ketone bodies, which are produced by fatty acid oxidation. Although the pathways involved in the ketogenic
diet are not entirely clear, the main effects of the production of ketone bodies appear to be neurotransmitter
modulation and antioxidant effects on the brain. This review highlights the impacts of the ketogenic diet on
the modulation of neurotransmitters, levels of biogenic monoamines and protective antioxidant mechanisms of
neurons. In addition, future perspectives are proposed.
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& INTRODUCTION
The ketogenic diet (KD) is particularly aimed at treating
children and adolescents with refractory epilepsy (drug-
refractory seizures), regardless of the etiology (1). Although
refractory epilepsy is the initial focus of this treatment,
clinical and epidemiologic studies indicate that chronic
epilepsy is followed by long-term behavioral changes and
cognitive degeneration even in an optimal state of anti-
epileptic drug therapy (2,3). Consequently, some authors
that the KD may be an early option for the treatment of
patients with epilepsy instead of the last choice. The KD is
also an important coadjuvant treatment for most refractory
and generalized epilepsies, such as Dravet, Doose, Lennox-
Gastaut and West syndromes (4).
The KD was developed in 1920 by Wilder (5) and many
studies have shown its positive benefits, including an over
50% reduction in seizures, which is considered to be clinically
relevant (6,7). The average time of treatment with the KD is
two years, after which it should be discontinued (1).
Recently, Hirano et al. (8) reported the positive effects of
the KD in children with West syndrome who were resistant
to adrenocorticotropic hormone (ACTH) therapy, which is a
first-line treatment for children with this syndrome. Among
the main effects observed in five out of six children in this
study included the disappearance of spasms in two children
and a decrease in their frequency by 80% in the other three
children. Similar positive effects of the KD were observed in
a study of 41 children with refractory epilepsy, in which the
number of seizures was reduced by 90% in 10.53% of the
children and by at least 50% in 36.84% of the children and
the seizures disappeared in 5.26% of the children (9).
The KD is based on high fat, low carbohydrate and
moderate protein levels and the production of ketone bodies
(KBs) from the oxidation of fat as the primary source of
metabolic energy, which appears to be involved in the
control of seizures (10).
The modified Atkins diet (MAD) is also used in the
treatment of patients with refractory epilepsy (11). As
opposed to the KD, there is no restriction on protein or
daily calorie intake in the MAD. This diet is composed of
60% fat, 30% protein and 10% carbohydrates (12). Although
the MAD is more palatable than the KD, its efficacy in
relation to the KD is unclear (11). In children with Lennox-
Gastaut syndrome, the MAD was effective and well
tolerated and the nine children on the diet showed an over
50% reduction in seizure frequency after one year of
treatment (13). However, a previous review showed that
37% of patients who were fed the KD had an additional
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decrease ($10%) in seizures compared with those who were
fed the MAD (14).
Regardless of the use of the MAD or the KD, in some
clinical situations, such as those involving patients with
glucose transporter 1 deficiency syndrome (GLUT1-DS),
these dietary treatments can be used as differentiating tools
for identifying patients with metabolic diseases because
these patients are generally seizure-free after the introduc-
tion of the diet (15).
Previously, the KD protocol recommended that the diet
be initiated after a fasting period of 12-48 h, during which
the child must stay at a hospital (1). As described in the
references, many centers begin the diet without fasting
because several studies have found no difference in the use
of fasting versus non-fasting in clinical practice (5). The
introduction of the KD following specific requirements (fat-
to-carbohydrate and -protein ratios) and the subsequent
control of seizures usually occur when these ratios are 3:1 or
4:1, which are the most commonly used proportions (16).
Diets containing lower proportions (2:1) are normally used
when the treatment is introduced (10).
The KD is usually well tolerated and increasing numbers
of studies in the literature are reporting its benefits.
However, the metabolic pathways involved in the produc-
tion of KBs have not been well established despite nearly
one century of research. This review highlights the main
neurobiochemical mechanisms that have been studied over
the past 15 years according to original and review studies
indexed in the MedLine/PubMed database.
Anticonvulsant mechanisms and ketone bodies
There are many hypotheses regarding the antiepileptic
mechanisms of the KD. The early hypotheses regarding its
activities were focused on the concepts of acidosis,
dehydration and increased ketone concentrations (17).
Other factors, such as c-aminobutyric acid (GABA) and
glutamate, membrane potentials, ion channels, biogenic
monoamines and neuroprotective activities (Figure 1), have
been studied in experimental models (in vivo or in vitro).
Although the mechanism by which the KD exerts its
anticonvulsant effects is unclear, these effects are often
associated with important metabolic changes that induce
increased levels of KBs, mainly b-hydroxybutyrate and
acetoacetate (18,19).
Energy metabolism in the brain involves distinct and
complex pathways. Under physiological conditions, most
precursors of KBs are long-chain fatty acids. They are
released from adipose tissue in response to a decrease in
blood glucose, such as that which occurs during fasting (20).
Similar mechanisms are involved in the KD, during which
long-chain fatty acids are metabolized in the liver and
converted into KBs. These fatty acids are oxidized in the
mitochondria, producing high levels of acetyl-CoA, which
cannot be oxidized in the Krebs cycle. The excess acetyl-
CoA is converted to acetoacetate and subsequently to
acetone and b-hydroxybutyrate (21). The KBs cross the
blood-brain barrier and are transported by monocarboxylic
acid transporters to the brain interstitial space, the glia and
the neurons. In these tissues, the KBs act as substrates in the
Krebs cycle and respiratory chain, contributing to brain
energy metabolism (21).
Currently, there is no evidence that dehydration or fluid
restriction is necessary for the clinical efficacy of the KD
(17). Furthermore, this diet has been associated with pH
changes that directly influence the behaviors of ion channels
and neurotransmitter receptors (17).
Some studies have suggested that the KD is more effective
in children than in adults. There are high levels of ketone-
metabolizing enzymes in the brain and their capacities for
taking up ketone bodies are higher in infancy than in
adulthood (18,21). The number of monocarboxylic acid
transporters decreases with cerebral maturation and they
are present at low levels in adulthood (21). Despite these
differences, adaptive cerebral metabolic changes occur in
adults who are exposed to stress situations, such as
ischemia, trauma and sepsis (22). As shown in the literature,
there are increases in the concentrations of ketone-depen-
dent monocarboxylic acid transporters in these situations,
indicating that KD treatment in adults is feasible (22,23).
Several studies of the mechanisms of action of the KD
have been based on animal models, allowing for the
investigators to examine the anatomical, chemical, cellular,
molecular and functional changes that occur following
seizures (24,25). Different animal models have been used
that have been exposed to electrical and chemical stimula-
tion and physical, genetic and spontaneous seizure models
have been employed that simulate different types of
epileptic seizures (17,21,26). Table 1 shows the main
outcomes reported in recent years.
The in vivo and in vitro models have revealed the different
anticonvulsant properties and antiepileptic effects of the
KD. These aspects have been studied primarily in models of
non-epileptic rodents receiving the KD that are later
exposed to proconvulsant agents or electrical stimuli (18).
However, the levels of therapeutic KBs and the specific
effects of each ketone body have not been clearly elucidated.
In 2003, Likhodii et al. (27) administered intraperitoneal
injection of acute acetone to rats in increasing doses from 2
to 32 mmol/kg. These authors observed an increase in the
protective effect of acetone against seizures as the dose
increased in four different models: maximal electroshock,
subcutaneous pentylenetetrazol, amygdala kindling and
AY-9944 (27). Gaisor et al. (26) showed similar results
following the administration of acetone (1-32 mmol/kg) to
juvenile mice, which was shown to protect them from
seizures induced by pentylenetetrazol and 4-aminopyridine.
However, acetone doses of $10 mmol/kg promoted toxic
effects in the pentylenetetrazol model, generating motor
impairment in the mice.
Modulation of neurotransmitters
The major mechanisms proposed to explain the increased
inhibition and/or decreased excitation that are induced by
the KD involve the neurotransmitters GABA and glutamate
(28). KBs act not only as energy sources but also contribute
to reducing glucose consumption in the brain by modulat-
ing the activities of neurotransmitters (29).
Changes in the levels of glutamate and GABA, which are
the major excitatory and inhibitory neurotransmitters,
respectively and their receptors have been proposed as the
possible mechanisms of action of the KD (30). GABA is an
intermediate of a-ketoglutarate, which is synthesized in the
Krebs cycle (via glutamate) and converted into GABA by
glutamate decarboxylase (21). Moreover, KBs inhibit gluta-
mate decarboxylase and decreased levels stimulate the
synthesis of GABA, thus contributing to seizure control (31).
In previous experimental studies, animals were fed the
KD and were observed to have higher concentrations of
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b-hydroxybutyrate in the forebrain and cerebellum, indicat-
ing increased GABA levels (32). Astrocytes and neuroglial
cells, which are also enriched with this enzyme during
ketone metabolism, utilize KBs as energy sources (23,33).
Suzuki et al. (33) suggested that the inhibition of GABA-
transaminase mRNA expression was mainly dependent on
b-hydroxybutyrate in astrocytes following the presence of
increased GABA levels in the brain (33). This allows
glutamate to be more available for GABA synthesis,
favoring the hypothesis that b-hydroxybutyrate leads to
the inhibition of neuronal firing following recurrent
neuronal activity (34).
Similar results were observed in a clinical study in which
the GABA levels of responders were higher compared with
those of non-responders following treatment with the KD
(30). However, an evaluation of the dependence of this
Figure 1 - Production of ketone bodies and potential primary anticonvulsant mechanisms: (1) GABA neurotransmitter (neuronal
hyperpolarization and membrane channels; (2) inactivation of VGLUT and inhibition of glutamate neurotransmitter; (3) modified
concentrations of biogenic monoamines; and (4) antioxidant mechanism of diminishing reactive oxygen species. For more information,
please see text.
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response on the levels of b-hydroxybutyrate was not
performed.
Increased inhibition or decreased excitability, if suffi-
ciently intense, may influence the normal functioning of the
brain in addition to controlling seizures (28). Furthermore,
high GABA levels appear to stimulate chloride channel
receptors, increasing the influx of negatively charged ions
and consequently inducing neuronal hyperpolarization (32).
This event is responsible for inhibiting the activation of
sodium and calcium channels, the activities of which are
required for neuronal excitation. KBs possibly contribute to
the activities of KATP channels, which experience activity-
dependent opening and could partially explain the reduced
numbers of epileptic seizures (34).
In contrast to the high levels of GABA, the glutamate-to-
ketone ratio can modulate glutamate physiological function-
ing through VGLUT, which is responsible for filling
presynaptic vesicles with glutamate in a Cl--dependent
manner (35). An in vitro study showed that Cl- is an
allosteric activator of VGLUT, which is competitively
inhibited by KBs (more often by acetoacetate than by b-
hydroxybutyrate) (36).
Biogenic monoamines
The modulation of biogenic monoamine levels was
proposed as a plausible mechanism for explaining the
anticonvulsant effects of the KD. However, the specific
mechanisms underlying such activities remain unclear
(17,19,37,38).
In animal models, norepinephrine levels have been
shown to increase in rats receiving the KD (37). This
beneficial effect of the KD was not observed when
norepinephrine transport was inhibited, suggesting that
the noradrenergic system is required for the neuroprotective
effects of the KD to occur. A similar profile was observed in
norepinephrine transporter knockout mice fed normal diets
(38).
A clinical study on biogenic monoamines in the cere-
brospinal fluid of children treated with the KD showed that
their dopamine and serotonin levels were significantly
reduced [from 410 to 342 and from 158 to 137 nmol/L
(16.6 and 13.3% reductions), respectively] after a three-
month treatment, whereas their norepinephrine levels [from
51.7 to 51.0 nmol/L (1.4% reduction)] remained unchanged
(19). These authors proposed that changes in monoamine
levels are also dependent upon whether children are
respondent or non-respondent to the KD.
Some authors have suggested that adenosine is the major
seizure inhibitory neuromodulator and that the KD exerts a
regulatory role in relation to this monoamine (39). This
hypothesis was reinforced by Fedele et al. (40), who used
transgenic mice for adenosine A1 receptors (A1Rs) and
revealed the presence of spontaneous hippocampal electro-
graphic seizures due to the overexpression of adenosine.
Recently, the positive impact of the KD was assessed in
transgenic mice with or without adenosine A1Rs. In the
mice with A1Rs that were fed the KD, seizures were nearly
abolished after four weeks of treatment. In contrast, these
effects were not observed in the mice lacking these receptors
(41).
Thus, the KD increases adenosine levels. However, its
efficiency in the control of seizures depends on the
expression of the A1Rs (39).
Neuroprotective mechanisms
Many studies have shown that the epileptogenic state
involves complex molecular pathways in which oxidative
stress and mitochondrial dysfunction may exert important
roles in neuronal programmed/controlled (apoptosis) or
uncontrolled/passive (necrosis) cell death (42). Thus,
investigators have given particular emphasis to the mod-
ulation of the mitochondrial biogenesis of neurons by the
KD and caloric restriction, highlighting the neuroprotective
role of the mitochondria as the primary key to the control of
apoptosis and cell death (43,44,45,46,47,48).
Mitochondria are intracellular organelles that primarily
function in the production of cellular energy in the form of
adenosine triphosphate (ATP). This nucleotide is produced
by the mitochondrial respiratory chain through oxidative
phosphorylation, which is performed by five multienzyme
complexes (complexes I-V). The dysfunction of complex I
may lead to decreased ATP production, which is commonly
observed in neuronal diseases (42,49). In prolonged sei-
zures, a temporary reduction in ATP levels can contribute to
cell death (50).
Bought et al. (43) showed that mice that were fed the KD
for at least three weeks showed a 46% increase in the
hippocampal biogenesis of mitochondria compared with the
control animals. In addition, these authors observed that 39
out of 42 regulated transcripts encoding mitochondrial
proteins were up-regulated, implying increased ATP pro-
duction and the capacity of this diet to stabilize neuronal
membrane potentials (43).
The mitochondria are the major organelles that are
responsible for reducing O2 to non-oxidative substances.
However, when the mitochondrial respiratory chain is
deregulated (the dysfunctioning of calcium homeostasis
and imbalances of membrane potentials), decreased rates of
ATP generation and the overproduction of reactive oxygen
species (ROS) occur (49,51). In normal conditions, 1-5% of
O2 in the mitochondrial electron transport chain is not
reduced to H2O, CO2 and ATP, stimulating the generation
of ROS [H2O2, O2N-, nitric oxide (NO) and peroxinitrite]
(52).
Regarding coupled changes that occur during ROS
production, other authors (44) have observed that rats that
were fed the KD for 10-12 days showed significant increases
in uncoupling protein (UCPs) levels in their hippocampal
mitochondria. These responses were related to the 15%
decrease in ROS levels in the hippocampi of these animals
(44). Both effects were associated with mitochondrial
biogenesis and the maintenance of calcium homeostasis
(43,44).
The protective effects of the KD on oxidative stress have
also been observed in the antioxidant system, particularly
involving glutathione (GSH), which exhibits an increased
capacity for peroxide detoxification within the cell (47). In
juvenile rats that were fed the KD for three weeks, increased
levels of mitochondrial-reduced GSH and an increased ratio
of GSH to oxidized glutathione (GSSG) were observed,
suggesting that the KD improves hippocampal redox
statuses and protects mitochondrial DNA from oxidative
stress. During seizures, these antioxidants are depleted and
oxidative stress is stimulated (45).
Recently, some studies (46,48) have reviewed these
mechanisms, emphasizing that the beneficial effects of the
KD also involve caloric restriction. In addition to the
increased levels of UCPs and the decreased production of
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ROS, these authors also reported other mechanisms
involved in the control of seizures, such as decreases in
both insulin-like growth factor 1 (IGF-1) and the mamma-
lian target of rapamycin (mTOR) and increases in both
sirtuins and adenosine monophosphate-activated protein
kinase (AMPK).
Sirtuins are deacetylases with multiple functions related
to fat oxidation and increased mitochondrial size and
number. The increased expression of sirtuins may be
associated with the inhibition of IGF-1 after caloric restric-
tion (46,48). In addition, the increase in AMPK is directly
related to ATP production (48).
The mTOR protein kinase is involved in multiple and
complex activities in the body, participating in specific
mechanisms in the nervous system. Thus, it is an exciting
target for new horizons in drug discovery (53). Brain
abnormalities are associated with the hyperactivation of
the mTOR pathway and the KD may play an important role
in inhibiting this pathway, thus conferring anticonvulsant
effects. However, the underlying mechanisms are still
unknown and require further exploration (48,53).
It is important to recognize that seizures stimulate the
production of free radicals and mitochondrial dysfunction,
resulting in a chronic redox state, neuronal changes and an
increased susceptibility to seizures, leading to epilepsy (42).
As a result, the KD improves the stability of the mitochon-
drial membrane and increases the efficiency of O2 consump-
tion, stimulating the generation of ATP and minimizing the
oxidative stress-induced epileptogenic state and mitochon-
drial dysfunction.
Future perspectives
Considering the aforementioned studies, we have verified
that the mechanisms of action of KBs, which are involved in
the reduction of epileptic seizures, are distinct and complex.
In addition, the major mechanisms proposed to date are
based on experimental models and few clinical studies,
which have small sample sizes and uncontrolled designs.
Furthermore, the multiple etiologies of epilepsy represent
an important limitation to the understanding of the
relationships between the KD, KBs and neuronal mechan-
isms in the control of seizures. Thus, we propose the
following: I - that physical or chemical mechanisms
employed to induce seizures should follow standardized
protocols; II - that the physiological levels of KBs should be
more frequently considered in experimental treatments; III -
that the etiologies of epilepsy are better characterized in
future clinical trials; IV - that biomarkers of treatment
efficacies (levels of KBs, GABA and monoamines) are
evaluated; V - that the potential side effects of treatments
are systematically monitored; and VI - that novel mechan-
isms of action of KBs are evaluated. In consideration of these
proposals, positive clinical responses to the KD remain the
principal goal of this treatment. Thus, given the current state
of the research, we also propose that KD intervention
should be included early in clinical protocols for the
treatment of children and adolescents with refractory
epilepsy and not only as the last therapeutic option.
& ACKNOWLEDGMENTS
The authors acknowledge the financial support from the State of Sa˜o Paulo
Research Foundation (FAPESP # 12/03775-0), National Institute for
Science and Technology of Complex Fluids (INCT-FCx-USP) and Group
for Research on Complex Fluids (NAP-FCx-USP).
& AUTHOR CONTRIBUTIONS
Lima PA designed and coordinated the study, prepared the table, proposed
the main facets of the study, was in charge of the analysis and quality
control of the data, illustrated the figure and wrote the first draft of the
manuscript. Damasceno NR designed and coordinated the study, prepared
the table and critically reviewed the manuscript. Sampaio LP proposed the
main facets of the study and revised the manuscript. All authors
contributed to the interpretation of the data and approved the final
version of the manuscript.
& REFERENCES
1. Kossoff EH, Zupec-Kania BA, Amark PE, Ballaban-Gil KR, Christina
Bergqvist A, Blackford R, et al. Optimal clinical management of children
receiving the ketogenic diet: recommendations of the International
Ketogenic Diet Study Group. Epilepsia. 2009;50(2):304-17, http://dx.doi.
org/10.1111/j.1528-1167.2008.01765.x.
2. Cendes F. Progressive hippocampal and extrahippocampal atrophy in
drug resistant epilepsy. Curr Opin Neurol. 2005;18(2):173-7, http://dx.
doi.org/10.1097/01.wco.0000162860.49842.90.
3. Sutula TP, Hagen J, Pitka¨nen A. Do epileptic seizures damage the brain?
Curr Opin Neurol. 2003;16(2):189-95, http://dx.doi.org/10.1097/
00019052-200304000-00012.
4. Wang H, Lin K. Ketogenic diet: An early option for epilepsy treatment,
instead of a last choice only. Biomedical Journal. 2013;36(1):16, http://
dx.doi.org/10.4103/2319-4170.107155.
5. Wilder R. The effect of ketonemia on the course of epilepsy. Mayo Clinic
Bulletin. 1921;2:307.
6. Neal EG, Chaffe H, Schwartz RH, Lawson MS, Edwards N, Fitzsimmons
G, et al. The ketogenic diet for the treatment of childhood epilepsy: a
randomised controlled trial. Lancet Neurology. 2008;7(6):500-6, http://
dx.doi.org/10.1016/S1474-4422(08)70092-9.
7. De Kinderen RJ, Lambrechts DA, Postulart D, Kessels AG, Hendriksen
JG, Aldenkamp AP, et al. Research into the (Cost-) effectiveness of the
ketogenic diet among children and adolescents with intractable epilepsy:
design of a randomized controlled trial. BMC Neurology. 2011;11(1):10,
http://dx.doi.org/10.1186/1471-2377-11-10.
8. Hirano Y, Oguni H, Shiota M, Nishikawa A, Osawa M. Ketogenic diet
therapy can improve ACTH-resistant West syndrome in Japan. Brain
Dev. 2014.
9. Pablos-Sa´nchez T, Oliveros-Leal L, Nu´n˜ez-Enamorado N, Camacho-
Salas A, Moreno-Villares JM, Simo´n-De las Heras R. The use of the
ketogenic diet as treatment for refractory epilepsy in the paediatric age.
Rev Neurol. 2014;58(2):55-62.
10. Lee PR, Kossoff EH. Dietary treatments for epilepsy: management guide-
lines for the general practitioner. Epilepsy & Behavior. 2011;21(2):115-21,
http://dx.doi.org/10.1016/j.yebeh.2011.03.008.
11. Sharma S, Jain P. The Modified Atkins Diet in Refractory Epilepsy.
Epilepsy Res Treat. 2014;2014:404202.
12. Kossoff EH. More fat and fewer seizures: dietary therapies for epilepsy.
Lancet Neurol. 2004;3(7):415-20, http://dx.doi.org/10.1016/S1474-4422
(04)00807-5.
13. Sharma S, Jain P, Gulati S, Sankhyan N, Agarwala A. Use of the Modified
Atkins Diet in Lennox Gastaut Syndrome. J Child Neurol. 2014.
14. Kossoff EH, Bosarge JL, Miranda MJ, Wiemer-Kruel A, Kang HC, Kim
HD. Will seizure control improve by switching from the modified Atkins
diet to the traditional ketogenic diet? Epilepsia. 2010;51(12):2496-9,
http://dx.doi.org/10.1111/j.1528-1167.2010.02774.x.
15. Ramm-Pettersen A, Nakken KO, Haavardsholm KC, Selmer KK.
Occurrence of GLUT1 deficiency syndrome in patients treated with
ketogenic diet. Epilepsy Behav. 2014;32:76-8, http://dx.doi.org/10.1016/
j.yebeh.2014.01.003.
16. Kim DW, Kang HC, Park JC, Kim HD. Benefits of the nonfasting ketogenic
diet compared with the initial fasting ketogenic diet. Pediatrics.
2004;114(6):1627-30, http://dx.doi.org/10.1542/peds.2004-1001.
17. Masino SA, Rho JM. Mechanisms of ketogenic diet action. In: Noebls JL,
Avoli M, Rogawski MA, Olsen RW, Delgado-Escueta AV, editors.
Jasper’s Basic Mechanisms of the Epilepsies. 4th edition. Bethesda (MD):
National Center for Biotechnology Information (US); 2012.
18. Freeman JM, Kossoff EH, Hartman AL. The ketogenic diet: one decade
later. Pediatrics. 2007;119(3):535-43, http://dx.doi.org/10.1542/peds.
2006-2447.
19. Dahlin M, Ma˚nsson J-E, A˚mark P. CSF levels of dopamine and serotonin,
but not norepinephrine, metabolites are influenced by the ketogenic diet
in children with epilepsy. Epilepsy Research. 2012;99(1):132-8, http://dx.
doi.org/10.1016/j.eplepsyres.2011.11.003.
20. Kossoff EH, Hartman AL. Ketogenic diets: new advances for metabo-
lism-based therapies. Current Opinion in Neurology. 2012;25(2):173-8,
http://dx.doi.org/10.1097/WCO.0b013e3283515e4a.
Mechanisms of a ketogenic diet
de Lima PA et al.
CLINICS 2014;69(10):699-705
704
21. McNally MA, Hartman AL. Ketone bodies in epilepsy. Journal of
Neurochemistry. 2012;121(1):28-35, http://dx.doi.org/10.1111/j.1471-4159.
2012.07670.x.
22. Prins ML. Cerebral metabolic adaptation and ketone metabolism after
brain injury. Journal of Cerebral Blood Flow & Metabolism. 2008;28(1):
1-16, http://dx.doi.org/10.1038/sj.jcbfm.9600543.
23. Klein P, Janousek J, Barber A, Weissberger R. Ketogenic diet treatment in
adults with refractory epilepsy. Epilepsy Behav. 2010;19(4):575-79, http://dx.
doi.org/10.1016/j.yebeh.2010.09.016.
24. Fisher RS. Animal models of the epilepsies. Brain Res Brain Res Rev.
1989;14(3):245-78, http://dx.doi.org/10.1016/0165-0173(89)90003-9.
25. Lo¨scher W. Animal models of intractable epilepsy. Prog Neurobiol.
1997;53(2):239-58, http://dx.doi.org/10.1016/S0301-0082(97)00035-X.
26. Gasior M, French A, Joy MT, Tang RS, Hartman AL, Rogawski MA. The
anticonvulsant activity of acetone, the major ketone body in the ketogenic
diet, is not dependent on its metabolites acetol, 1, 2-propanediol, methyl-
glyoxal, or pyruvic acid. Epilepsia. 2007;48(4):793-800, http://dx.doi.org/
10.1111/j.1528-1167.2007.01026.x.
27. Likhodii SS, Serbanescu I, Cortez MA, Murphy P, Snead OC, Burnham
WM. Anticonvulsant properties of acetone, a brain ketone elevated by
the ketogenic diet. Annals of Neurology. 2003;54(2):219-26, http://dx.
doi.org/10.1002/ana.10634.
28. Ruskin DN, Masino SA. The nervous system and metabolic dysregula-
tion: emerging evidence converges on ketogenic diet therapy. Front
Neurosci. 2012;6:33, http://dx.doi.org/10.3389/fnins.2012.00033.
29. LaManna JC, Salem N, Puchowicz M, Erokwu B, Koppaka S, Flask C, Lee
Z. Ketones suppress brain glucose consumption. Adv Exp Med Biol.
2009;645:301-6, http://dx.doi.org/10.1007/978-0-387-85998-9_45.
30. Dahlin M, Elfving A˚, Ungerstedt U, A˚mark P. The ketogenic diet
influences the levels of excitatory and inhibitory amino acids in the CSF
in children with refractory epilepsy. Epilepsy Res. 2005;64(3):115-25,
http://dx.doi.org/10.1016/j.eplepsyres.2005.03.008.
31. Neal E, Cross J. Efficacy of dietary treatments for epilepsy. J Hum Nutr
Diet. 2010;23(2):113-9, http://dx.doi.org/10.1111/j.1365-277X.2010.01043.x.
32. Yudkoff M, Daikhin Y, Nissim I, Lazarow A, Nissim I. Brain amino acid
metabolism and ketosis. J Neurosci Res. 2001;66(2):272-81, http://dx.doi.
org/10.1002/jnr.1221.
33. Suzuki Y, Takahashi H, Fukuda M, Hino H, Kobayashi K, Tanaka J, et al.
b-hydroxybutyrate alters GABA-transaminase activity in cultured astro-
cytes. Brain Res. 2009;1268(1):17-23, http://dx.doi.org/10.1016/j.brainres.
2009.02.074.
34. Tanner GR, Lutas A, Martı´nez-Franc¸ois JR, Yellen G. Single KATP
channel opening in response to action potential firing in mouse dentate
granule neurons. J Neurosci. 2011;31(23):8689-96, http://dx.doi.org/10.
1523/JNEUROSCI.5951-10.2011.
35. Omote H, Miyaji T, Juge N, Moriyama Y. Vesicular neurotransmitter
transporter: bioenergetics and regulation of glutamate transport.
Biochemistry. 2011;50(25):5558-65, http://dx.doi.org/10.1021/bi200567k.
36. Juge N, Gray JA, Omote H, Miyaji T, Inoue T, Hara C, et al. Metabolic
control of vesicular glutamate transport and release. Neuron. 2010;68(1):99-
112, http://dx.doi.org/10.1016/j.neuron.2010.09.002.
37. Weinshenker D. The contribution of norepinephrine and orexigenic
neuropeptides to the anticonvulsant effect of the ketogenic diet. Epilepsia.
2008;49(s8):104-7, http://dx.doi.org/10.1111/j.1528-1167.2008.01850.x.
38. Martillotti J, Weinshenker D, Liles LC, Eagles DA. A ketogenic diet and
knockout of the norepinephrine transporter both reduce seizure severity
in mice. Epilepsy Res. 2006;68(3):207-11, http://dx.doi.org/10.1016/j.
eplepsyres.2005.11.002.
39. Masino SA, Kawamura M, Wasser CD, Pomeroy LT, Ruskin DN.
Adenosine, ketogenic diet and epilepsy: the emerging therapeutic relation-
ship between metabolism and brain activity. Curr Neuropharmacol.
2009;7(3)257-68.
40. Fedele DE, Gouder N, Gu¨ttinger M, Gabernet L, Scheurer L, Ru¨licke T,
et al. Astrogliosis in epilepsy leads to overexpression of adenosine kinase,
resulting in seizure aggravation. Brain. 2005;128(10):2383-95, http://dx.
doi.org/10.1093/brain/awh555.
41. Masino SA, Li T, Theofilas P, Sandau US, Ruskin DN, Fredholm BB, et al.
A ketogenic diet suppresses seizures in mice through adenosine A1
receptors. J Clin Invest. 2011;121(7):2679-83, http://dx.doi.org/10.1172/
JCI57813.
42. Chuang YC. Mitochondrial dysfunction and oxidative stress in seizure-
induced neuronal cell death. Acta Neurol Taiwan. 2010;19(1):3-15.
43. Bough KJ, Wetherington J, Hassel B, Pare JF, Gawryluk JW, Greene JG,
et al. Mitochondrial biogenesis in the anticonvulsant mechanism of the
ketogenic diet. Ann Neurol. 2006;60(2):223-35, http://dx.doi.org/10.
1002/ana.20899.
44. Sullivan PG, Rippy NA, Dorenbos K, Concepcion RC, Agarwal AK, Rho
JM. The ketogenic diet increases mitochondrial uncoupling protein levels
and activity. Ann Neurol. 2004;55(4):576-80, http://dx.doi.org/10.1002/
ana.20062.
45. Jarrett SG, Milder JB, Liang LP, Patel M. The ketogenic diet increases
mitochondrial glutathione levels. J Neurochem. 2008;106(3):1044-51,
http://dx.doi.org/10.1111/j.1471-4159.2008.05460.x.
46. Maalouf M, Rho JM, Mattson MP. The neuroprotective properties of
calorie restriction, the ketogenic diet, and ketone bodies. Brain Res Rev.
2009;59(2):293-315, http://dx.doi.org/10.1016/j.brainresrev.2008.09.002.
47. Milder J, Patel M. Modulation of oxidative stress and mitochondrial
function by the ketogenic diet. Epilepsy Res. 2012;100(3):295-303, http://
dx.doi.org/10.1016/j.eplepsyres.2011.09.021.
48. Yuen AW, Sander JW. Rationale for using intermittent calorie restriction
as a dietary treatment for drug resistant epilepsy. Epilepsy Behav.
2014;33C:110-4, http://dx.doi.org/10.1016/j.yebeh.2014.02.026.
49. Cadenas E, Davies KJ. Mitochondrial free radical generation, oxidative
stress, and aging. Free Radic Biol Med. 2000;29(3-4):222-30, http://dx.
doi.org/10.1016/S0891-5849(00)00317-8.
50. Chuang YC, Lin JW, Chen SD, Lin TK, Liou CW, Lu CH, et al.
Preservation of mitochondrial integrity and energy metabolism during
experimental status epilepticus leads to neuronal apoptotic cell death in
the hippocampus of the rat. Seizure. 2009;18(6):420-8, http://dx.doi.org/
10.1016/j.seizure.2009.03.002.
51. Patel M. Mitochondrial dysfunction and oxidative stress: cause and
consequence of epileptic seizures. Free Radic Biol Med. 2004;37(12):1951-
62, http://dx.doi.org/10.1016/j.freeradbiomed.2004.08.021.
52. Halliwell B. Role of free radicals in the neurodegenerative diseases:
therapeutic implications for antioxidant treatment. Drugs Aging. 2001;
18(9):685-716, http://dx.doi.org/10.2165/00002512-200118090-00004.
53. Maiese K, Chong ZZ, Shang YC, Wang S. mTOR: on target for novel
therapeutic strategies in the nervous system. Trends Mol Med. 2013;
19(1):51-60, http://dx.doi.org/10.1016/j.molmed.2012.11.001.
CLINICS 2014;69(10):699-705 Mechanisms of a ketogenic diet
de Lima PA et al.
705
